MarketMindUS Markets Closed
AI-assisted · Not financial adviceNot adviceAI-assisted · Not financial advice.
IGC Pharma receives authorization for psilocybin research
2 Buy · 0 Hold · 0 Sell
Based on curated news sources (not retail comments)
Over the last 7 days: The regulatory authorization for psilocybin research and strong trial enrollment progress are strong bullish indicators, with no bear risks noted.